Patents Assigned to SUNGKWANG MEDICAL FOUNDATION
-
Publication number: 20240043800Abstract: Provided is a method of differentiating a pluripotent stem cell-derived hemogenic endothelial cell into a lymphoid lineage blood cell, enabling a hemogenic endothelial cell to be cultured for a long period of time so as to be induced into a lymphoid lineage blood cell, thereby facilitating induction of generation of immune cells such as T cells, B cells, and NK cells.Type: ApplicationFiled: February 4, 2022Publication date: February 8, 2024Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: Ji Yoon LEE, Ah Reum LEE, Jung Eun PARK
-
Publication number: 20240026451Abstract: Provided are a composition for diagnosing Down syndrome, a kit including the composition, a diagnostic method, and a method of providing information for diagnosing Down syndrome, the composition including an agent for measuring a methylation level of any one gene selected from the group consisting of MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP, PITX2, SH3BP2, SEPP1, FLJ32255, SHROOM1, LINC00574, LOC154449, PRRT4, TMEM176B, MNX1, LOC101928483, EGFL7, NACC2, C9orf69, TLX1, FGF8, TACC2, CPXM2, NKX6-2, TLXINB, IQSEC3, PCDH8, F7, SOX9, PNMAL2, THBD, MAPK81P2, KLHDC7B, GPR143, IGHMBP2, MRGPRD, CHODL, NCAM2, CYYR1, GRIK1, OLIG2, CLIC6, SIM2, HLCS, MX2, MX1, TMPRSS2, SLC37A1, PDE9A, CBS, CRYAA, C21orf2, TRPM2, TSPEAR, LINC00162, SSR4P1, SLC19A1, LOC100129027, MCM3AP, YBEY, PRMT2, and ITSN1. Thus, Down syndrome can be diagnosed early with high accuracy, and the disclosure is expected to be applied as key a technology in the field of Down syndrome diagnosis.Type: ApplicationFiled: May 7, 2021Publication date: January 25, 2024Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: Hyun Mee RYU, Ji Hyae LIM
-
Publication number: 20230390326Abstract: According to a composition including a cationic substance as an active ingredient according to one aspect, the stability of perforin protein is increased to induce the accumulation of intracellular perforin proteins, thereby increasing the activity of immune cells.Type: ApplicationFiled: October 27, 2021Publication date: December 7, 2023Applicants: SUNGKWANG MEDICAL FOUNDATION, CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Kyung-Soon PARK, Keun-Hong PARK, Seung Hee CHOI, Hye Jin KIM, Hee Jung AN
-
Publication number: 20230365932Abstract: Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.Type: ApplicationFiled: July 17, 2023Publication date: November 16, 2023Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: Hee Jung AN, Yeon Ho CHOI, Eun Jin LIM, Yong Wha MOON, Se Wha KIM
-
Publication number: 20230330151Abstract: Provided are a composition and a method for promoting differentiation of neural stem cells into dopaminergic neurons, the composition including fusaric acid, ascorbic acid, nicotinamide adenine dinucleotide, or a combination thereof. The composition and method according to an aspect may not only increase differentiation of neural stem cells isolated at an early stage of development into dopaminergic neurons, but also increase differentiation of subcultured neural stem cells into dopaminergic neurons, and thus, it is possible to secure more dopaminergic neurons, and increase therapeutic effects on Parkinson's disease.Type: ApplicationFiled: August 24, 2021Publication date: October 19, 2023Applicants: CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SUNGKWANG MEDICAL FOUNDATIONInventors: Jisook MOON, Chul KIM, Jae Hyun PARK, Ji-Min PARK, Young Sook SONG, Chul Woo LIM, Yuri CHOI
-
Publication number: 20230332079Abstract: The present disclosure relates to a biomimetic chip for three-dimensionally simulating an endometrium, and an endometrium simulating method using the biomimetic chip. The biomimetic chip according to an embodiment of the present disclosure is a three-dimensional biomimetic chip including a plate, a plurality of chambers, and a plurality of posts, which are arranged between the plurality of chambers, wherein the plurality of chambers include channels in which different cells are cultured, are arranged on the plate to be parallel to each other in one direction, and are arranged adjacent to each other such that at least some sections communicate with each other.Type: ApplicationFiled: June 23, 2021Publication date: October 19, 2023Applicants: CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SUNGKWANG MEDICAL FOUNDATIONInventors: Youn Jung KANG, Jung Ho AHN, Min Ji YOON, Hwi Jae CHA, Seon Hwa HONG
-
Patent number: 11746327Abstract: Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.Type: GrantFiled: November 20, 2018Date of Patent: September 5, 2023Assignee: SUNGKWANG MEDICAL FOUNDATIONInventors: Hee Jung An, Yeon Ho Choi, Eun Jin Lim, Yong Wha Moon, Se Wha Kim
-
Publication number: 20230265512Abstract: Provided are a method of providing information for diagnosing Down syndrome and a method of diagnosing Down syndrome, the method comprising measuring a methylation level of a Down syndrome biomarker in a biological sample separated from a fetus, comparing the measured methylation level of the biomarker with a methylation level of the first biomarker and the second biomarker in the biological sample separated from a normal control group, and determining a presence or a risk of Down syndrome by comparing the methylation level, wherein the biomarker is a first biomarker present on chromosome 21, a second biomarker present on a chromosome other than chromosome 21, or a combination thereof. Thus, Down syndrome can be diagnosed early with high accuracy, and the disclosure is expected to be applied as a key technology in the field of Down syndrome diagnosis.Type: ApplicationFiled: May 7, 2021Publication date: August 24, 2023Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: Hyun Mee RYU, Ji Hyae LIM
-
Publication number: 20230257364Abstract: Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an AXL-, Mer-, and/or c-Met-mediated disease using an effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER, and/or c-Met is inhibited, the compound or pharmaceutically acceptable salt thereof can re-sensitize cancer cells, such as non-small cell lung cancer cells, that have grown resistant to an anti-cancer agent.Type: ApplicationFiled: January 30, 2023Publication date: August 17, 2023Applicants: CMG Pharmaceutical Co., Ltd., Sungkwang Medical FoundationInventors: Jin Sung KIM, Sungmoo KIM, Ju Hui JEONG, Hyun Sook AN, Soojeong KIM
-
Composition, kit, and method for diagnosis and treatment of taxane anticancer agent-resistant cancer
Patent number: 11639531Abstract: According to a composition, kit, and method for diagnosing resistance to a taxane anticancer agent, a composition for treating taxane cancer agent-resistant cancers, and a method for screening materials for the same, taxane anticancer agent-resistant cancers may be efficiently diagnosed or treated, and candidate materials that may treat taxane anticancer agent-resistant cancers may be efficiently screened.Type: GrantFiled: March 20, 2019Date of Patent: May 2, 2023Assignee: SUNGKWANG MEDICAL FOUNDATIONInventors: Hee Jung An, Tae Heon Kim, Hae Youn Kang -
Publication number: 20230116621Abstract: Provided is a drug delivery carrier including PLGA and ?-cyclodextrin containing a drug. According to the drug delivery carrier, the time during which a drug stays in the living body may be prolonged, and due to the biodegradation thereof, few side effects occur.Type: ApplicationFiled: October 15, 2021Publication date: April 13, 2023Applicants: SELJIN CO.LTD., SUNGKWANG MEDICAL FOUNDATIONInventors: Seil SOHN, Wan Kyu KO, Daye LEE, Seong Jun KIM, Gong Ho HAN
-
Publication number: 20230113221Abstract: The disclosure relates to a method of producing bankable and subculturable mature microglia, and according to a method according to an aspect, subculture and banking are possible, and freeze storage and thawing are also possible, and thus, it is possible to simply isolate and use only mature microglia whenever necessary. In addition, it is possible to dramatically reduce the number of subjects required for an experiment, and therefore, the method may contribute economically to all research or industrial fields related to microglia.Type: ApplicationFiled: November 10, 2020Publication date: April 13, 2023Applicants: SUNGKWANG MEDICAL FOUNDATION, CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Min Soo KWON, Jong Seop RIM, Tae Ho KONG, Min Jung YOU, Ji Hye WON
-
Publication number: 20230035339Abstract: Provided are: a composition for diagnosing pre-eclampsia; a kit; a method of diagnosing pre-eclampsia using the same; and a method of providing information on diagnosis of pre-eclampsia. The composition, the kit, and the methods provide the effect of enabling the accurate and sensitive diagnosis of pre-eclampsia in a subject.Type: ApplicationFiled: December 28, 2020Publication date: February 2, 2023Applicants: SUNGKWANG MEDICAL FOUNDATION, UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITYInventors: Hyun Mee RYU, Ji Hyae LIM, Kwang Pyo KIM
-
Publication number: 20230002833Abstract: The disclosure relates to biomarkers for predicting a therapeutic response of a patient to an immune therapy. Since gene signatures and markers according to an aspect have an excellent predictive capacity for predicting a patient's therapeutic response to an immune therapy, a patient group predicted to exhibit therapeutic effects may be selected to perform an appropriate treatment, and a patient's suffering and costs may be reduced.Type: ApplicationFiled: November 10, 2020Publication date: January 5, 2023Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: So Hyun HWANG, Jae Joon LIM, Kwang Yul CHA, Hee Jung AN, Hae Youn KANG, Kyung Gi CHO, Jin Hyung HEO, Je-Gun JOUNG, Se Wha KIM, Ah Young KWON
-
Patent number: 11524036Abstract: Provided is a composition including mesenchymal stem cells as an effective ingredient for prevention, alleviation, or treatment of thyroid-associated ophthalmopathy. A pharmaceutical composition including mesenchymal stem cells as an effective ingredient for treatment of thyroid-associated ophthalmopathy allows patients with thyroid-associated ophthalmopathy to recover from an abnormal increase in hyaluronic acid production in orbital fibroblasts, increased adipocyte differentiation, and increased lipid accumulation, and thus may be useful for the treatment of thyroid-associated ophthalmopathy.Type: GrantFiled: August 16, 2018Date of Patent: December 13, 2022Assignee: SUNGKWANG MEDICAL FOUNDATIONInventors: He Len Lew, Mi Ra Park, Gi Jin Kim
-
Publication number: 20220296649Abstract: Provided are a method of preparing a spheroid of stem cells and a composition including the spheroid prepared by the method, the method including: culturing stem cells in a medium supplemented with matrilin-3 protein; and performing 3D cell culture on the cultured stem cells in the medium. The composition disclosed herein has effects of preventing or treating cartilage disease. In detail, the composition may be able to further promote cartilage differentiation of adult stem cells and reduce dedifferentiation and hypertrophy that may occur during cartilage regeneration, thereby providing a more effective cartilage tissue regeneration method.Type: ApplicationFiled: August 11, 2020Publication date: September 22, 2022Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: In Bo HAN, Hye Min CHOI
-
Patent number: 11370758Abstract: Provided is an inhibitor of an indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) of formula (I) or a pharmaceutically acceptable salt thereof: in which W1, W2, W3, and W4, X, Y, Z1, Z2, and R1-7 are described herein. Further provided is a method of treating or preventing a IDO and/or TDO-mediated disease using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 22, 2019Date of Patent: June 28, 2022Assignees: CMG PHARMACEUTICAL CO., LTD., SUNGKWANG MEDICAL FOUNDATIONInventors: Hong Jae Jeon, Chan Kim, Na Keum Lee, Jin Sung Kim, Hye Sun Jeon, Young Eun Kwon, Ju Hui Jeong
-
Publication number: 20220168121Abstract: The present invention provides a drug-eluting stent. The present invention includes a main structure, and a drug delivery layer that is applied to the main structure and includes a fibrosis drug, wherein, when the main structure comes into contact with a target tissue, the fibrosis drug of the drug delivery layer is released into the target tissue to perform fibrous of the target tissue.Type: ApplicationFiled: March 25, 2020Publication date: June 2, 2022Applicants: SUNGKWANG MEDICAL FOUNDATION, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Jung Hoon SUNG, Bo Young JUNG, Pil Sung YANG
-
COMPOSITION, KIT, AND METHOD FOR DIAGNOSIS AND TREATMENT OF TAXANE ANTICANCER AGENT-RESISTANT CANCER
Publication number: 20220119888Abstract: According to a composition, kit, and method for diagnosing resistance to a taxane anticancer agent, a composition for treating taxane cancer agent-resistant cancers, and a method for screening materials for the same, taxane anticancer agent-resistant cancers may be efficiently diagnosed or treated, and candidate materials that may treat taxane anticancer agent-resistant cancers may be efficiently screened.Type: ApplicationFiled: March 20, 2019Publication date: April 21, 2022Applicant: SUNGKWANG MEDICAL FOUNDATIONInventors: Hee Jung AN, Tae Heon KIM, Hae Youn KANG -
Publication number: 20220010280Abstract: Provided is a composition for inhibiting, preventing, alleviating, or treating adipogenesis. Mesenchymal stem cells according to one aspect or a composition comprising the same inhibit fat accumulation or adipose tissue increase and thus may be advantageously utilized in the prevention, treatment, or alleviation of diseases associated with abnormal fat metabolism.Type: ApplicationFiled: November 22, 2019Publication date: January 13, 2022Applicants: CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SUNGKWANG MEDICAL FOUNDATIONInventors: Gi Jin KIM, Jae Yeon KIM, He Len LEW